**7. Cyanobacterial drug discovery**

Systems biology can help us with the acquisition consciousness of the ways living systems function using computational power [65]. So as to study some specific facts in a definite biosynthetic pathway, some information about both the proteins in

charge and the responsible gene of that event is needed. The function of linking the chemical diversity of natural bioactive products and genomes in addition to modeling and prediction by incorporating such biological information could offer considerable information for the understanding of such a complex biological system [2].

According to the Comprehensive Microbial Resource Declaration, the genome sequences of human pathogenic bacteria and non-homologous in humans, have been documented. This could be an appropriate technique for the reporting of the new drug [66], and the improvements in synthetic biology now provide a solution to cyanobacteria being stubborn to genetic manipulation, opening up cyanobacteria as a valuable source of new enzymes and novel natural bioactive products.

Today pharmaceutical industry is concentrated on prominent output screening systems, genomics tools, and bioinformatics, containing combinatorial chemistry and logical design for the recognition of new bioactive compounds [29]. Recognizing groups of secondary bioactive compounds biosynthetic gene clusters with possible therapeutic competence involvement in an initial stage, which is conducted by the chemical structure of the identified bioactive compounds in cyanobacteria strains [3]. Cyanobacterial biologically active compounds are produced through NRPS, PKS, and mixed NRPS-PKS pathways [4]. Cyanobacteria strains presentation progressive screening outcomes are then designated for proteome mining and genomic characterization in order to classify biosynthetic gene clusters responsible for proteins connected to the making of these bioactive components [2]. This is imaginable because databases of biosynthetic gene clusters and cyanobacterial chemicals have been gathered through gene libraries (http://dtp.nci.nih.gov/docs/3d\_database/dis3d.html, NCBI Pubchem http://pubchem.ncbi.nlm.nih.gov/, ChemIDPlus http://chem.sis.nlm. nih.gov/chemidplus, ANTIMIC [67], and Super Natural Database http://bioinformatics.charite.de/supernatural/) [68]. As a result of the increased antibiotic resistance, available drugs are effective against only one-third of the diseases, and the identification of new biologically active compounds is thus urgently necessary [29].
